Blueprint Medicines Corporation

Clinical trials sponsored by Blueprint Medicines Corporation, explained in plain language.

Now part of Sanofi S.A. SNY NASDAQ

A precision medicine company developing targeted therapies for cancer and rare diseases.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

New pill could tame stubborn hives that antihistamines Can't stop Results expected Dec 2026 (estimated)
New drug aims to ease symptoms of rare mast cell disease Results expected Jun 2027 (estimated)

Browse trials soon ready across all sponsors →

Trials to join now! 6 Not yet finished but already full! 2 Completed 4 Terminated 1

New cancer drug BLU-222 tested in early trial – but study stopped early

Disease control Stopped early

This early-phase trial tested a new drug called BLU-222, alone or with other medicines, in about 50 people with advanced solid tumors (including certain breast, ovarian, and stomach cancers). The goal was to find a safe dose and see if it shrinks tumors. However, the study was te…

Phase 1 • Sponsor: Blueprint Medicines Corporation • Aim: Disease control

Last updated Jun 27, 2026 08:00 UTC

Blueprint Medicines Corporation

Upcoming readouts

New cancer drug BLU-222 tested in early trial – but study stopped early